| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 04/28/2005 | US20050089526 Monomeric unit of the complex containin HIV-1 gp120 and HIV-1 gp41, (ii) the gp4l has one or more mutations in its N-terminal helix, and (iii) the gp120 and gp41 are bound to each other by a disulfide bond between a cysteine residue introduced into the gp120 and a cysteine residue introduced into gp41 |
| 04/28/2005 | US20050089524 Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
| 04/28/2005 | US20050089521 Methods for treating taxol-induced sensory neuropathy |
| 04/28/2005 | US20050089520 Antibody stimulating il-ira production |
| 04/28/2005 | US20050089519 Bispecific anti-cd19x anti-cd16 antibodies and uses thereof |
| 04/28/2005 | US20050089518 Prospective identification and characterization of breast cancer stem cells |
| 04/28/2005 | US20050089517 for treating respiratory diseases: asthma, allergic rhinitis, atopic dermatitis, nasal polyposis, Churg-Strauss syndrome, sinusitis, and chronic obstructive pulmonary disease (COPD), administering an antibody (i,e Daclizumab) that binds specifically to an IL-2 receptor |
| 04/28/2005 | US20050089510 Immunization against plaque forming diseases such as cardiovascular disorders with vaccines for disaggregation |
| 04/28/2005 | CA2762955A1 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| 04/28/2005 | CA2548551A1 Shc proteins as therapeutic targets in proliferative diseases |
| 04/28/2005 | CA2545539A1 Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| 04/28/2005 | CA2543447A1 Antibody and use of the same |
| 04/28/2005 | CA2542823A1 Method for prognostic evaluation of carcinoma using anti-p-lap antibody |
| 04/28/2005 | CA2542691A1 Il-6 antagonist for use as mesothelioma therapeutic agent |
| 04/28/2005 | CA2542638A1 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| 04/28/2005 | CA2542618A1 Chimeric metabotropic glutamate receptors and uses thereof |
| 04/28/2005 | CA2542508A1 Novel igg3 antibodies for stimulating phagocytosis |
| 04/28/2005 | CA2542482A1 Ztnfr14, a tumor necrosis factor receptor |
| 04/28/2005 | CA2542128A1 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| 04/28/2005 | CA2542084A1 A method for the separation anti-amyloid beta antibody with amyloid beta peptide |
| 04/27/2005 | EP1526185A1 Use of a microorganism or cell to induce autoimmunization of an organism against a tumor |
| 04/27/2005 | EP1526183A2 Dimer of a peptide derived from the C-terminal sequence of human superoxide dismutase facilitating the penetration of a substance into cells and/or cell nuclei |
| 04/27/2005 | EP1526175A2 Coronavirus, nucleic acid, protein and methods for the generation of vaccine, medicaments and diagnostics |
| 04/27/2005 | EP1526171A1 Simultaneous stimulation and concentration of cells |
| 04/27/2005 | EP1525480A1 Multiple hybrid immunoassay |
| 04/27/2005 | EP1525323A2 Pgc-beta, a novel pgc-1 homologue and uses therefor |
| 04/27/2005 | EP1525313A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemaggllutinin/esterase |
| 04/27/2005 | EP1525311A2 Protein complexes of the tip60 transcriptional activator protein as well as components, fragments and derivatives thereof and methods for using the same |
| 04/27/2005 | EP1525223A2 Ox40 (=cd134) receptor agonists and therapeutic use |
| 04/27/2005 | EP1524995A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 04/27/2005 | EP1141271B1 Selection of monoclonal antibodies |
| 04/27/2005 | EP1135153B1 Uses for eph receptor antagonists and agonists to treat vascular disorders |
| 04/27/2005 | EP1039931B1 Multivalent recombinant antibodies for treating hrv infections |
| 04/27/2005 | EP0935470B1 Method for treating allergic lung disease |
| 04/27/2005 | EP0743983B1 Mammalian thymokine genes |
| 04/27/2005 | CN1610754A Enzymes having dehalogenase activity and methods of use thereof |
| 04/27/2005 | CN1610751A Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof |
| 04/27/2005 | CN1610743A Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 04/27/2005 | CN1610697A E type hepatitis virus monoclonal antibody or its conjugated active fragment and use thereof |
| 04/27/2005 | CN1610696A Antibodies that immunospecifically bind to TRAIL receptors |
| 04/27/2005 | CN1610695A Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| 04/27/2005 | CN1609617A Composition and method for diagnosing and preventing serious acute respiratory syndrome(SARS) |
| 04/27/2005 | CN1609616A Specific markers for diabetes |
| 04/27/2005 | CN1609213A Gene cloning of polyepitope antigen of hepatitis C virus and its coding sequence |
| 04/27/2005 | CN1609206A Crystal structure of oxidosqualene cyclase |
| 04/27/2005 | CN1609203A Human ovary carcinoma resisting monoclonal antibody hybridoma cell line and its monoclonal antibody and application |
| 04/27/2005 | CN1609123A Variable region sequence of hepatitis B virus monoclonal antibody, gene engineering antibody containing the variable region and its use |
| 04/27/2005 | CN1609120A Cotton verticillium wilt germ secreted exciton gene and its application |
| 04/27/2005 | CN1198936C Alzheimer's disease secretase |
| 04/27/2005 | CN1198933C Epitopes of protein pre-M/M of dengue virus, synthetic peptides |
| 04/27/2005 | CN1198932C Streptococcus pneumoniae antigens |
| 04/27/2005 | CN1198931C MOraxella catarrhalis BASB034 polypeptides and uses thereof |
| 04/27/2005 | CN1198929C Antibodies against interferon alpha/beta receptor |
| 04/27/2005 | CN1198845C Monoclonal antibody inducing programming apoptosis |
| 04/27/2005 | CN1198836C Nucleic acids encoding G-protein coupled receptor involved in sensory |
| 04/27/2005 | CN1198648C High affinity human monoclonal antibodies specific for RSV F-protein |
| 04/27/2005 | CN1198647C Antibodies against human CD40 |
| 04/27/2005 | CN1198646C Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens |
| 04/27/2005 | CN1198642C Pharmaceutical application of mammal cell kinetin synthetic inhibitory factor |
| 04/26/2005 | US6884879 Anti-VEGF antibodies |
| 04/26/2005 | US6884873 Kit for determining DNA double-stranded breaks with anti-γ-H2A antibodies |
| 04/26/2005 | US6884618 Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
| 04/26/2005 | US6884597 Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or enhancers of these enzymes |
| 04/26/2005 | US6884590 Kit for detecting restriction fragnemt length polymorphism in intracellular adhesion molecules and diagnosing inflammatory bowel disease |
| 04/26/2005 | US6884574 Methods of identifying agents which inhibit GPR-9-6 |
| 04/26/2005 | US6884418 Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
| 04/26/2005 | US6884417 Sepsis |
| 04/26/2005 | CA2310854C Isolation and identification of novel polymerases |
| 04/26/2005 | CA2253871C Ret ligand (retl) for stimulating neural and renal growth |
| 04/26/2005 | CA2165954C Prostaglandin receptor fp and dna encoding it |
| 04/24/2005 | CA2446391A1 Method for inducing t cells regulator with cd47 ligands |
| 04/21/2005 | WO2005035778A1 PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE |
| 04/21/2005 | WO2005035768A1 Expression of biologically active polypeptides in duckweed |
| 04/21/2005 | WO2005035756A1 Bispecific antibody substituting for functional proteins |
| 04/21/2005 | WO2005035754A1 Double specific antibodies substituting for functional protein |
| 04/21/2005 | WO2005035753A1 Double specific antibodies substituting for functional protein |
| 04/21/2005 | WO2005035741A1 Genomically modified cell |
| 04/21/2005 | WO2005035732A2 Papp-a ligands |
| 04/21/2005 | WO2005035721A2 Native immunoglobulin binding reagents and methods for making and using same |
| 04/21/2005 | WO2005035720A2 Methods and use of binding components for improving assay specificity |
| 04/21/2005 | WO2005035713A2 Alternatively spliced variants of human cox1 |
| 04/21/2005 | WO2005035586A1 Fused protein composition |
| 04/21/2005 | WO2005035585A1 Support having affinity for antibody |
| 04/21/2005 | WO2005035584A1 Fully human antibodies against human 4-1bb (cd137) |
| 04/21/2005 | WO2005035583A1 Antibody composition specifically binding to il-5 receptor |
| 04/21/2005 | WO2005035582A1 Composition of antibody capable of specifically binding ccr4 |
| 04/21/2005 | WO2005035581A1 COMPOSITION OF ANTIBODY CAPABLE OF SPECIFICALLY BINDING HUMAN VEGF RECEPTOR Flt-1 |
| 04/21/2005 | WO2005035580A1 Single-chain antibody acting against 37 kda/67 kda laminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof |
| 04/21/2005 | WO2005035578A1 Antibody composition specifically binding to ganglioside gm2 |
| 04/21/2005 | WO2005035577A1 Antibody composition specifically binding to ganglioside gd3 |
| 04/21/2005 | WO2005035576A2 Method of resisting osteoclast formation |
| 04/21/2005 | WO2005035575A2 Humanization of antibodies |
| 04/21/2005 | WO2005035574A1 IgM HIGH CONCENTRATION STABILIZED SOLUTION |
| 04/21/2005 | WO2005035573A1 Method of stabilizing proteion solutions |
| 04/21/2005 | WO2005035572A2 Antibody compositions and methods |
| 04/21/2005 | WO2005035567A1 Chimeric mhc protein and oligomer thereof for specific targeting |
| 04/21/2005 | WO2005035558A2 Piscirickettsia salmonis antigens and use thereof |
| 04/21/2005 | WO2005035548A1 The moduilation of hyaluronan synthesis and degradation in the treatment of disease |
| 04/21/2005 | WO2005034996A1 An augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses |
| 04/21/2005 | WO2005034995A1 Prion chimeras and uses thereof |